Cargando…

Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report

BACKGROUND: Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by accumulation of phospholipoproteinaceous material in the alveoli. The presentation is nonspecific but typically includes dyspnea; the spectrum of disease includes rapidly progressive hypoxic respiratory failure....

Descripción completa

Detalles Bibliográficos
Autores principales: Boyce, Dacia S. K., Lee, John W., Shah, Phalgoon, Freeman, Judy H., Aboudara, Matthew C., Hostler, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417025/
https://www.ncbi.nlm.nih.gov/pubmed/30866900
http://dx.doi.org/10.1186/s12890-019-0822-x
_version_ 1783403481032294400
author Boyce, Dacia S. K.
Lee, John W.
Shah, Phalgoon
Freeman, Judy H.
Aboudara, Matthew C.
Hostler, David C.
author_facet Boyce, Dacia S. K.
Lee, John W.
Shah, Phalgoon
Freeman, Judy H.
Aboudara, Matthew C.
Hostler, David C.
author_sort Boyce, Dacia S. K.
collection PubMed
description BACKGROUND: Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by accumulation of phospholipoproteinaceous material in the alveoli. The presentation is nonspecific but typically includes dyspnea; the spectrum of disease includes rapidly progressive hypoxic respiratory failure. Whole lung lavage (WLL) is the treatment of choice in symptomatic PAP, but transient worsening of oxygenation sometimes requires salvage modalities of support such as extracorporeal membrane oxygenation (ECMO). Granulocyte macrophage colony-stimulating factor (GM-CSF) plays a role in the pathophysiology of PAP. We highlight a case of severe PAP treated with exogenous GM-CSF and sequential lobar lavage due to the unavailability of salvage methods of oxygenation. CASE PRESENTATION: A 36 year old female was admitted with fevers, chills, and progressive dyspnea. On presentation she was tachypneic, tachycardic, and hypoxemic; labs revealed leukocytosis and lactic acidosis. Chest CT identified diffuse ground glass opacities in a ‘crazy-paving’ pattern. Following intubation due to impending respiratory failure, bronchoscopy with bronchoalveolar lavage was performed. The lavage return stained positive with Periodic Acid Schiff, confirming the diagnosis of PAP. Continued deterioration necessitated treatment; however, at this geographically remote center without ECMO services WLL was judged to carry significant risk. Nebulized GM-CSF was administered without significant improvement. Subcutaneous GM-CSF was administered and isolated subsegmental lavages of the bilateral upper lobes were performed, with rapid improvement in oxygenation. Additional sequential lobar lavage and continued GM-CSF therapy as an outpatient resulted in complete resolution of oxygen requirement and return to normal pulmonary physiology. CONCLUSIONS: The autoimmune form of PAP is the most common, indicating that therapy with GM-CSF may play an important role for many patients. Treatment with WLL may be impractical in some clinical settings due to the expertise and salvage modalities required. Sequential lobar lavage requires less specialized expertise and may incur less risk of refractory hypoxemia. We posit that this combined-modality therapy is ideally suited to geographically-remote centers such as our own.
format Online
Article
Text
id pubmed-6417025
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64170252019-03-25 Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report Boyce, Dacia S. K. Lee, John W. Shah, Phalgoon Freeman, Judy H. Aboudara, Matthew C. Hostler, David C. BMC Pulm Med Case Report BACKGROUND: Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by accumulation of phospholipoproteinaceous material in the alveoli. The presentation is nonspecific but typically includes dyspnea; the spectrum of disease includes rapidly progressive hypoxic respiratory failure. Whole lung lavage (WLL) is the treatment of choice in symptomatic PAP, but transient worsening of oxygenation sometimes requires salvage modalities of support such as extracorporeal membrane oxygenation (ECMO). Granulocyte macrophage colony-stimulating factor (GM-CSF) plays a role in the pathophysiology of PAP. We highlight a case of severe PAP treated with exogenous GM-CSF and sequential lobar lavage due to the unavailability of salvage methods of oxygenation. CASE PRESENTATION: A 36 year old female was admitted with fevers, chills, and progressive dyspnea. On presentation she was tachypneic, tachycardic, and hypoxemic; labs revealed leukocytosis and lactic acidosis. Chest CT identified diffuse ground glass opacities in a ‘crazy-paving’ pattern. Following intubation due to impending respiratory failure, bronchoscopy with bronchoalveolar lavage was performed. The lavage return stained positive with Periodic Acid Schiff, confirming the diagnosis of PAP. Continued deterioration necessitated treatment; however, at this geographically remote center without ECMO services WLL was judged to carry significant risk. Nebulized GM-CSF was administered without significant improvement. Subcutaneous GM-CSF was administered and isolated subsegmental lavages of the bilateral upper lobes were performed, with rapid improvement in oxygenation. Additional sequential lobar lavage and continued GM-CSF therapy as an outpatient resulted in complete resolution of oxygen requirement and return to normal pulmonary physiology. CONCLUSIONS: The autoimmune form of PAP is the most common, indicating that therapy with GM-CSF may play an important role for many patients. Treatment with WLL may be impractical in some clinical settings due to the expertise and salvage modalities required. Sequential lobar lavage requires less specialized expertise and may incur less risk of refractory hypoxemia. We posit that this combined-modality therapy is ideally suited to geographically-remote centers such as our own. BioMed Central 2019-03-12 /pmc/articles/PMC6417025/ /pubmed/30866900 http://dx.doi.org/10.1186/s12890-019-0822-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Boyce, Dacia S. K.
Lee, John W.
Shah, Phalgoon
Freeman, Judy H.
Aboudara, Matthew C.
Hostler, David C.
Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report
title Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report
title_full Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report
title_fullStr Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report
title_full_unstemmed Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report
title_short Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report
title_sort combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417025/
https://www.ncbi.nlm.nih.gov/pubmed/30866900
http://dx.doi.org/10.1186/s12890-019-0822-x
work_keys_str_mv AT boycedaciask combinedmodalitytherapyforpulmonaryalveolarproteinosisinaremotesettingacasereport
AT leejohnw combinedmodalitytherapyforpulmonaryalveolarproteinosisinaremotesettingacasereport
AT shahphalgoon combinedmodalitytherapyforpulmonaryalveolarproteinosisinaremotesettingacasereport
AT freemanjudyh combinedmodalitytherapyforpulmonaryalveolarproteinosisinaremotesettingacasereport
AT aboudaramatthewc combinedmodalitytherapyforpulmonaryalveolarproteinosisinaremotesettingacasereport
AT hostlerdavidc combinedmodalitytherapyforpulmonaryalveolarproteinosisinaremotesettingacasereport